# Ollama command request
_Exported on 2/20/2026 at 01:42:36 GMT+5:30 from Cursor (2.5.17)_

---

**User**

give again that ollama command

---

**Cursor**


Searching the codebase for Ollama references to identify the command.



Common Ollama commands from your project docs:

**To download/pull a model:**
```bash
ollama pull llama3.2:3b
```

**To start the Ollama server:**
```bash
ollama serve
```

**Other useful commands:**
```bash
# List available models
ollama list

# Test if Ollama is running
curl http://localhost:11434/api/tags
```

Which one did you need? The most common are `ollama pull llama3.2:3b` (download model) and `ollama serve` (start server).

---

**User**

ok now i want to use the ollama llama3.2:3b for the LLM explanation

---

**Cursor**


Checking the current setup to ensure Ollama with llama3.2:3b is configured for LLM explanations.



The code already supports Ollama with `llama3.2:3b`. Creating a `.env` file in the backend directory to configure it:



Checking for an existing `.env` file and creating one if needed:



Creating the `.env` file with Ollama configuration for `llama3.2:3b`:



Configured Ollama to use `llama3.2:3b` for LLM explanations. Summary:

## Configuration complete

1. Created `.env` file in `phrama_guide/backend/` with:
   - `OLLAMA_BASE_URL=http://localhost:11434`
   - `OLLAMA_MODEL=llama3.2:3b`

2. Backend code is already set up — `main.py` reads these environment variables and uses Ollama for generating explanations.

## Next steps

1. Make sure Ollama is installed and the model is pulled:
   ```bash
   ollama pull llama3.2:3b
   ```

2. Start the Ollama server (if not already running):
   ```bash
   ollama serve
   ```

3. Start your backend server:
   ```bash
   cd phrama_guide/backend
   uvicorn main:app --reload
   ```

The backend will use Ollama with `llama3.2:3b` to generate pharmacogenomic explanations when analyzing VCF files. The LLM explanations will appear in the `llm_generated_explanation` field of the API response.

If Ollama isn't running or the model isn't available, the backend will gracefully fall back to placeholder messages without breaking the API.

---

**User**

for frontend 

---

**Cursor**


Checking the frontend setup to configure Ollama integration:



Checking the frontend configuration and updating it to use environment variables:



Updating the frontend to use environment variables for the API URL. The frontend doesn't call Ollama directly; it calls the backend, which uses Ollama. Configuring environment variables:



Updating the frontend to use environment variables and fixing the API URL:



Enhancing the frontend to display the full LLM explanation (summary and mechanism):



Updating the frontend to display the full LLM explanation, including the mechanism and source:



Configured the frontend for Ollama integration. Summary:

## Frontend configuration complete

### Changes made

1. Updated API URL configuration:
   - Changed from hardcoded `http://localhost:3000` to use environment variable
   - Defaults to `http://localhost:8000` (FastAPI default port)
   - Uses `VITE_API_BASE_URL` from environment

2. Created environment files:
   - `.env` — local development configuration
   - `.env.example` — template for reference

3. Updated Vite config:
   - Added `envPrefix: "VITE_"` to expose environment variables

4. Enhanced LLM explanation display:
   - Shows summary and mechanism separately
   - Displays the model source (e.g., "ollama_llama3.2:3b")
   - Shows cited variants if available

### How it works

The frontend doesn't connect directly to Ollama. Flow:
1. Frontend → Backend API (`http://localhost:8000/api/analyze`)
2. Backend → Ollama (`http://localhost:11434`) using `llama3.2:3b`
3. Backend → Frontend (returns results with LLM explanation)

### To use

1. Make sure Ollama is running:
   ```bash
   ollama serve
   ```

2. Make sure the model is pulled:
   ```bash
   ollama pull llama3.2:3b
   ```

3. Start the backend:
   ```bash
   cd phrama_guide/backend
   uvicorn main:app --reload
   ```

4. Start the frontend:
   ```bash
   cd phrama_guide/frontend
   npm run dev
   ```

The frontend will now display LLM-generated explanations from Ollama's `llama3.2:3b` model when you analyze VCF files.

---

**User**

ADD Provides dosing recommendations aligned with CPIC guidelines 

---

**Cursor**


Reviewing the current implementation, then adding CPIC-aligned dosing recommendations.



Adding CPIC-aligned dosing recommendations. Expanding the backend with detailed dosing guidance and updating the frontend to display it.



Adding CPIC-aligned dosing recommendations with specific doses, alternatives, and monitoring requirements:



Updating `build_drug_assessment` to include dosing recommendations in the response:



Updating `build_drug_assessment` to include CPIC dosing recommendations:



Updating the frontend to display CPIC dosing recommendations:



Updating the frontend to display CPIC dosing recommendations:



Adding a section to display CPIC dosing recommendations:



Checking for syntax errors:



Added CPIC-aligned dosing recommendations. Summary:

## CPIC dosing recommendations added

### Backend changes (`phrama_guide/backend/main.py`)

1. Expanded `PGX_RULES` dictionary with CPIC dosing data:
   - Action required (avoid, reduce_dose, consider_alternative, etc.)
   - Initial dose recommendations with specific dosages
   - Alternative drugs with dosing when applicable
   - Required monitoring parameters
   - CPIC guideline references (with publication years)
   - Clinical notes explaining the rationale

2. Updated `build_drug_assessment()`:
   - Extracts dosing recommendations from rules
   - Adds `cpic_dosing_recommendations` to the API response when available

### Frontend changes (`phrama_guide/frontend/src/App.tsx`)

1. Added TypeScript interfaces:
   - `CpicDosingRecommendations` interface
   - Updated `DrugResult` to include optional `cpic_dosing_recommendations`

2. Added UI section:
   - Displays CPIC dosing recommendations in a formatted card
   - Color-coded action indicators (red for avoid, yellow for reduce, etc.)
   - Lists alternative drugs
   - Shows required monitoring parameters
   - Displays CPIC guideline references
   - Includes clinical notes

### Features

- CPIC-aligned recommendations for all 6 supported drugs:
  - CODEINE (CYP2D6)
  - CLOPIDOGREL (CYP2C19)
  - WARFARIN (CYP2C9)
  - SIMVASTATIN (SLCO1B1)
  - AZATHIOPRINE (TPMT)
  - FLUOROURACIL (DPYD)

- Specific dosing guidance:
  - Exact dose reductions (e.g., "Reduce by 30-50%")
  - Alternative drug suggestions with dosing
  - Monitoring requirements (lab tests, frequency)

- CPIC guideline references:
  - Includes publication years and updates
  - Follows CPIC evidence levels

The frontend now displays these recommendations in a structured format, making it easier for clinicians to implement CPIC-aligned dosing decisions.

---

**User**

[
  {
    "patient_id": "PATIENT_001",
    "drug": "FLUOROURACIL",
    "timestamp": "2026-02-19T20:11:09.182724Z",
    "risk_assessment": {
      "risk_label": "Safe",
      "confidence_score": 0.6,
      "severity": "none"
    },
    "pharmacogenomic_profile": {
      "primary_gene": "DPYD",
      "diplotype": "*1/*1",
      "phenotype": "NM",
      "detected_variants": []
    },
    "clinical_recommendation": {
      "summary": "Use standard dosing with routine clinical monitoring."
    },
    "llm_generated_explanation": {
      "summary": "**Comprehensive Clinical Summary**\n\nThe patient is prescribed Fluorouracil for treatment of cancer. Given their DPYD diplotype (*1/*1) and normal metabolizer phenotype (NM), the risk assessment indicates that standard dosing with routine clinical monitoring is safe.\n\n**Biological Mechanism**\n\nDPYD encodes for dihydropyrimidine dehydrogenase (DPD), an enzyme responsible for the catabolism of Fluorouracil.",
      "mechanism": "The *1/*1 diplotype suggests that the patient's DPD enzyme function is normal, as indicated by a NM phenotype. This means that Fluorouracil will be metabolized and eliminated from the body in a manner similar to that of individuals with wild-type DPYD.\n\n**Citation**\n\nCPIC (Clinical Pharmacogenetics Implementation Consortium) guidelines recommend standard dosing for patients with DPYD NM phenotype, as their risk of severe toxicity is low. [1]\n\nReferences:\n\n[1] CPIC DPYD V-guideline. Clin Pharmacogenet. 2018;18(5):e123-e131.\n\nNote: No specific pharmacogenomic variants were detected in the patient's data, and the NM phenotype suggests that standard dosing with routine clinical monitoring is safe.",
      "cited_variants": [],
      "source": "ollama_llama3.2:3b"
    },
    "quality_metrics": {
      "vcf_parsing_success": true,
      "variant_count": 0,
      "gene_count": 3
    }
  }
] LITERALLY NO CHANGE

